CEL-SCI (CVM) Competitors

CEL-SCI (NYSE:CVM) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.

Do insiders & institutionals believe in CVM or CRBU?

12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 16.2% of CEL-SCI shares are owned by insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more volatility and risk, CVM or CRBU?

CEL-SCI has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500.

Does the MarketBeat Community favor CVM or CRBU?

Caribou Biosciences received 25 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 60.98% of users gave Caribou Biosciences an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.

Company	Underperform	Outperform
CEL-SCI	Outperform Votes No Votes	Underperform Votes 16 100.00%
Caribou Biosciences	Outperform Votes 25 60.98%	Underperform Votes 16 39.02%

Do analysts rate CVM or CRBU?

Caribou Biosciences has a consensus price target of $10.33, suggesting a potential upside of 688.80%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than CEL-SCI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CEL-SCI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Caribou Biosciences	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is CVM or CRBU more profitable?

CEL-SCI has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,290.81%. Caribou Biosciences' return on equity of -45.46% beat CEL-SCI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CEL-SCI	N/A	-238.05%	-104.65%
Caribou Biosciences	-1,290.81%	-45.46%	-38.07%

Does the media favor CVM or CRBU?

In the previous week, Caribou Biosciences had 15 more articles in the media than CEL-SCI. MarketBeat recorded 20 mentions for Caribou Biosciences and 5 mentions for CEL-SCI. Caribou Biosciences' average media sentiment score of 0.07 beat CEL-SCI's score of -0.42 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CEL-SCI	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Caribou Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable valuation and earnings, CVM or CRBU?

CEL-SCI has higher earnings, but lower revenue than Caribou Biosciences. CEL-SCI is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CEL-SCI	N/A	N/A	-$26.92M	-$0.48	-0.82
Caribou Biosciences	$34.48M	3.44	-$102.07M	-$1.65	-0.79

Summary

Caribou Biosciences beats CEL-SCI on 13 of the 17 factors compared between the two stocks.